Home › SEC Filings › Press Releases
Press Releases
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| MESO | PRESS-RELEASE | bullish | 7/10 | Mesoblast announced an exclusive worldwide license to a patented CAR-MSC technology platform from Mayo Clinic, acquired | Apr 14, 2026 |
| ALGS | PRESS-RELEASE | bullish | 7/10 | Aligos Therapeutics announced FDA Fast Track Designation for pevifoscorvir sodium in chronic HBV infection and an interi | Apr 14, 2026 |
| GRTX | PRESS-RELEASE | bearish | 7/10 | Galera Therapeutics (GRTX) is merging with private biotech Obsidian Therapeutics in an all-stock transaction, with the c | Apr 14, 2026 |
| ENTX | PRESS-RELEASE | neutral | 2/10 | Entera Bio announced a virtual Key Opinion Leader webinar on April 20, 2026, to discuss the osteoporosis treatment lands | Apr 14, 2026 |
| ACTU | PRESS-RELEASE | bullish | 8/10 | Actuate Therapeutics announced positive Phase 2 trial results for elraglusib in metastatic pancreatic cancer, showing a | Apr 14, 2026 |
| CLRB | PRESS-RELEASE | mixed | 6/10 | Cellectar Biosciences announced the first patient enrollment in its Phase 1b trial of CLR 125 for triple negative breast | Apr 14, 2026 |
| RNXT | PRESS-RELEASE | bullish | 7/10 | RenovoRx announced clinical data presented at SIR 2026 showing TAMP, enabled by its RenovoCath device, achieved reduced | Apr 14, 2026 |
| BMRA | PRESS-RELEASE | bullish | 6/10 | Biomerica announced the commercial launch of its inFoods® IBS diagnostic-guided therapy in Canada through partnerships w | Apr 14, 2026 |
| BIVI | PRESS-RELEASE | neutral | 4/10 | BioVie announced the acceptance of an abstract presenting baseline data from its SUNRISE-PD Phase 2 trial of bezisterim | Apr 14, 2026 |
| GRCE | PRESS-RELEASE | bullish | 7/10 | Grace Therapeutics announced that results from its STRIVE-ON Phase 3 safety trial for GTx-104, an IV formulation of nimo | Apr 14, 2026 |
| CMND | PRESS-RELEASE | bullish | 7/10 | Clearmind Medicine announced that its drug candidate CMND-100 met the primary safety and tolerability endpoint in the Ph | Apr 14, 2026 |
| PRAX | PRESS-RELEASE | bullish | 8/10 | Praxis Precision Medicines announced that the FDA has accepted its New Drug Application (NDA) for ulixacaltamide HCl to | Apr 14, 2026 |
| LGND | PRESS-RELEASE | bullish | 8/10 | Ligand Pharmaceuticals announced FDA approval for FILSPARI (sparsentan) to treat focal segmental glomerulosclerosis (FSG | Apr 14, 2026 |
| TLSA | PRESS-RELEASE | bullish | 7/10 | Tiziana Life Sciences announced that a late-breaking poster on its Phase 2a trial of intranasal foralumab in Multiple Sy | Apr 14, 2026 |
| BMRA | PRESS-RELEASE | mixed | 6/10 | Biomerica reported Q3 fiscal 2026 results with revenue down 11.6% YoY to $987K, driven by lower contract manufacturing, | Apr 13, 2026 |
| AIM | PRESS-RELEASE | bearish | 7/10 | AIM ImmunoTech disclosed that its 2025 audited financial statements include a going concern emphasis from its auditor, c | Apr 13, 2026 |
| XRTX | PRESS-RELEASE | bullish | 7/10 | XORTX Therapeutics has closed its acquisition of Vectus Biosystems' renal anti-fibrotic program, including the pre-IND a | Apr 13, 2026 |
| SYRE | PRESS-RELEASE | bearish | 7/10 | Spyre Therapeutics announced a $300 million public offering of common stock, with underwriters expected to receive a 30- | Apr 13, 2026 |
| CLLS | PRESS-RELEASE | bullish | 8/10 | Cellectis highlighted positive interim futility analysis results from Allogene's pivotal ALPHA3 trial of cema-cel, an al | Apr 13, 2026 |
| SANA | PRESS-RELEASE | bullish | 7/10 | Sana Biotechnology announced a strategic collaboration with Mayo Clinic to accelerate the development and clinical deliv | Apr 13, 2026 |
| ALLO | PRESS-RELEASE | bearish | 6/10 | Allogene Therapeutics announced a proposed public offering of $175 million in common stock, with underwriters granted a | Apr 13, 2026 |
| GEVO | PRESS-RELEASE | neutral | 3/10 | Gevo, Inc. announced the appointment of Joan Cetera as Vice President of Communications and Public Relations, part of a | Apr 13, 2026 |
| RVMD | PRESS-RELEASE | bearish | 7/10 | Revolution Medicines announced two concurrent capital raises: a $750 million common stock offering and a $250 million co | Apr 13, 2026 |
| PHGE | PRESS-RELEASE | bullish | 7/10 | BiomX (PHGE) announced a definitive agreement to acquire a controlling interest in DFSL, an Israeli defense engineering | Apr 13, 2026 |
| LIXT | PRESS-RELEASE | neutral | 5/10 | { "summary": "Lixte Biotechnology announced interim results from a Phase 1b trial combining its PP2A inhibitor LB-100 | Apr 13, 2026 |
| SEPN | PRESS-RELEASE | bullish | 7/10 | Septerna announced the dosing of the first participants in its Phase 1 trial of SEP-479, an oral small molecule PTH1R ag | Apr 13, 2026 |
| PCRX | PRESS-RELEASE | bullish | 7/10 | Pacira BioSciences presented real-world data at AMCP 2026 showing EXPAREL® use in outpatient joint replacement surgeries | Apr 13, 2026 |
| ELAB | PRESS-RELEASE | neutral | 4/10 | PMGC Holdings subsidiary NorthStrive Biosciences announced the transfer of the EL-32 Working Cell Bank to a U.S. third-p | Apr 13, 2026 |
| BFRG | PRESS-RELEASE | bullish | 7/10 | BullFrog AI announced a commercial feasibility agreement with a top 5 global pharmaceutical company to identify drug tar | Apr 13, 2026 |
| IMA | PRESS-RELEASE | bearish | 6/10 | ImageneBio (IMA) announced a $30 million private placement led by Coastlands Capital, with proceeds aimed at advancing i | Apr 13, 2026 |